Opevesostat

From WikiMD.com Medical Encyclopedia

Overview of the drug Opevesostat


Opevesostat
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


Opevesostat is a chemical compound that has been investigated for its potential use as a therapeutic agent. It is primarily known for its role as an inhibitor of the enzyme glutaminase, which is involved in the metabolism of glutamine.

Mechanism of Action[edit | edit source]

Opevesostat functions by inhibiting the activity of glutaminase, an enzyme that catalyzes the conversion of glutamine to glutamate. This process is crucial in the metabolic pathways of rapidly proliferating cells, such as cancer cells. By inhibiting glutaminase, Opevesostat disrupts the supply of glutamate, thereby affecting the tricarboxylic acid cycle and reducing the availability of energy and biosynthetic precursors necessary for cell growth and proliferation.

Therapeutic Potential[edit | edit source]

The inhibition of glutaminase by Opevesostat has been explored as a potential therapeutic strategy in the treatment of various types of cancer, including leukemia and solid tumors. Cancer cells often exhibit increased glutamine metabolism, making them more susceptible to glutaminase inhibitors. Opevesostat's ability to selectively target cancer cell metabolism while sparing normal cells offers a promising approach to cancer therapy.

Clinical Development[edit | edit source]

Opevesostat has undergone various stages of clinical trials to evaluate its safety, efficacy, and pharmacokinetics. These studies aim to determine the optimal dosing regimens and to identify any potential side effects associated with its use. The results of these trials will inform the future development and potential approval of Opevesostat as a cancer treatment.

Chemical Properties[edit | edit source]

Chemical structure of Opevesostat

Opevesostat is characterized by its specific chemical structure, which enables it to effectively bind to and inhibit glutaminase. The molecular design of Opevesostat allows for high specificity and potency, making it a valuable candidate for further drug development.

Research and Development[edit | edit source]

Research into Opevesostat continues to explore its full potential as a therapeutic agent. Ongoing studies are investigating its effects in combination with other cancer therapies, such as chemotherapy and immunotherapy. The goal is to enhance the overall efficacy of cancer treatment regimens and to overcome resistance mechanisms that may arise during therapy.

Related Pages[edit | edit source]

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD